FDA Clears Xenix Medical’s Riva Posterior Fixation System

Xenix Medical has earned U.S. Food and Drug Administration 510(k) clearance for the Riva Posterior Fixation System and subsequently launched the product to market.

The Riva Posterior Fixation System is designed with versatility and simplicity at its core, company bigwigs claim. Its simplistic modular design allows the surgeon to easily tailor the construct to each patient’s needs, even in the most challenging deformity, revision, or variable-anatomy cases.

A defining feature is the system’s single-step head attachment and removal mechanism, which allows surgeons to attach and detach the tulip head using simple, straightforward instrumentation, thereby streamlining intraoperative workflow. Upon attachment, surgeons receive both tactile and audible feedback confirming the tulip head is securely engaged to the screw shank, which provides an added layer of intraoperative assurance. The Riva tulip-to-shank interface has been engineered and tested to deliver strength equivalent to leading pre-assembled pedicle screw systems to give surgeons the versatility of a modular platform without biomechanical compromise.

“There are other modular systems on the market, but none give me the freedom to create my ideal construct for each patient like Riva,” commented Andrew Park, M.D., a partner at Texas Spine Consultants in Dallas. “Its wide array of screw heads simply and reliably attaches to a variety of screw shanks, giving me surgical control and operational efficiency that I just can’t get with anything else.”

The system is supported by various tulip head and screw shank configurations to enable surgeons to select the optimal components for challenging anatomical variations or complex constructs. This versatility allows for greater adaptability across a broad range of patient populations and procedures, obviating the need for separate implant systems.

The Riva Posterior Fixation System’s key features include:

• A modular head design with intuitive instrumentation
• An audible and tactile head-to-shank connection confirmation
• A full complement of tulip head and screw shank styles to accommodate complex anatomy and constructs
• A simplified instrument set designed to support operating room efficiency
• A foundational technological platform designed for scalability, with plans for future expansion, including advanced surface technology, sacropelvic fixation options, and MIS capabilities

Having completed the launch, Xenix Medical has incorporated early clinical feedback into its full commercial rollout strategy. The firm is actively expanding its U.S. distribution network and surgeon access.

The company is working to integrate its proprietary NanoACTIV surface technology into the Riva system, leveraging NanoACTIV’s advanced surface characteristics. In addition, Xenix Medical is developing an expanded portfolio of sacropelvic fixation and attachment options, which will extend the system’s capability to address complex deformity and long-construct cases requiring pelvic anchoring.

Xenix Medical also plans to extend the Riva system to minimally invasive surgery (MIS), enabling surgeons to leverage the system’s modular design and versatile implant options through MIS approaches. This extension will broaden the patient population that can benefit from the Riva platform while supporting the continued industry shift toward less invasive surgical techniques.

“Riva’s full commercial launch is a significant milestone, but it is just the next step in our accelerating trajectory,” Xenix Medical President Ryan Phillips stated. “We will be rolling out several additional differentiated technologies and enhancements to our current portfolio over the coming weeks and months. Stay tuned.”

Xenix Medical is a medical device company developing spinal fixation solutions that improve surgical outcomes and simplify procedures. The company strives to raise the standard of spinal surgery through thoughtful engineering that stretches beyond industry norms.